Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical
presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; …

Parkinson's disease is increasingly prevalent. It progresses from the pre-motor stage
(characterised by non-motor symptoms like REM sleep behaviour disorder), to the disabling …

Alpha-synuclein seed amplification assays (αSyn-SAAs) are promising diagnostic tools for
Parkinson's disease (PD) and related synucleinopathies. They enable detection of seeding …

Parkinson's disease (PD) is a neurodegenerative disorder where alpha-synuclein plays a
central role in the death and dysfunction of neurons, both, in central, as well as in the …

Prasinezumab, a monoclonal antibody that binds aggregated α-synuclein, is being
investigated as a potential disease-modifying therapy in early-stage Parkinson's disease …

A major challenge in Parkinson's disease is the variability in symptoms and rates of
progression, underpinned by heterogeneity of pathological processes. Biomarkers are …

With the advent of the genetic era in Parkinson's disease (PD) research in 1997, α-synuclein
was identified as an important player in a complex neurodegenerative disease that affects> …

Background Neurofilament light chain protein (NfL) is a promising biomarker of
neurodegeneration. Objectives To determine whether plasma and CSF NfL (1) associate …

According to the Geroscience concept that organismal aging and age-associated diseases
share the same basic molecular mechanisms, the identification of biomarkers of age that can …